A multi-way sensitivity analysis was performed to examine a best case scenario in which the point estimate for the 36H regimen was significant, the cost of the regimens was reduced to $20 by excluding clinic visits and liver function test costs (assuming these would be included in routine HIV costs when HIV and TB care were co-localized) and ART was initiated at a CD4 count ≤350 cells/mm3. This evidence concerns the gene CD4 and tuberculosis.